Selective internal radiation therapy
Ask the expert
The report presents a summary of reimbursement situation for selective internal radiation therapy in Europe.
The following indications will be considered:
- Primary liver cancer (hepatocellular carcinoma);
- Metastatic liver cancer.
Different types of microspheres for SIRT will be covered in the report, including those use the radionuclide yttrium-90 and based on the radionuclide holmium-166.
The only reimbursement within public / statutory health insurance systems is considered. The results will be provided for hospital settings.
Report includes essential information about reimbursement and national funding, including:
- Brief overview of reimbursement system for medical devices
- Procedure coding for technology
- Diagnosis coding
- Payment mechanism for technology
- Reimbursement tariffs for technology
- Restrictions in indications or scenarios for use of technology
- Policy considerations by payers and policy-makers about technology
Reimbursement information is provided for the following geographies:
- England (UK)
It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.
Manufacturers of treatment of selective internal radiation therapy (SIRT):
- Bio-Rad (Bio-Rex, Aminex)
- BTG (TheraSphere)
- Sirtex (Sir-spheres)
- Terumo (QuiremScout, QuiremSpheres)
Table of content is not available at the moment. Report is still ongoing.
On March 31, 2021, NICE published Technology Appraisal Guidance on selective internal radiation therapies (SIRT) for treating hepatocellular carcinoma (HCC). Technology Appraisal is the only NICE program that has a direct link with the acceptance of technologies by payers. Payers need to implement the recommended technologies within three months after the publication of the guidance. Medical devices are very rarely evaluated within the Technology Appraisal program. SIR-Spheres and TheraSphere were recommended to treat unresectable advanced HCC under certain conditions, while QuiremSpheres was not recommended.Read more
On March 30, 2020, the Dutch Healthcare Institute (Zorginstituut Nederland, ZIN) announced five projects which received a subsidy under the "Subsidy scheme for promising care" in 2021: repetitive transcranial magnetic stimulation and in vivo exposure with response prevention in obsessive-compulsive disorder; MRI-guided laser-induced thermotherapy in glioblastoma; personalized treatment with selective internal radiotherapy in elderly or vulnerable colon cancer patients with liver metastases; structured, multidisciplinary and person-centered intensive care aftercare for patients at risk of health problems; Basophil Activation Test in children with possible IgE mediated cow's milk allergy.Read more
On February 24, 2021, NHS England published an update of the Specialized Services Policy Pipeline (covering period November 10, 2020 - February 10, 2021). Two new Clinical Commissioning Policies were added to the work program, and seven new policies were published, including stereotactic ablative radiotherapy, stereotactic radiosurgery and proton therapy. The status of ongoing policies was updated as well.Read more
In January 2021, the National Institute for Health and Care Excellence (NICE) published two new interventional procedure guidance (self-expanding implant insertion into the intersphincteric space for faecal incontinence and minimally invasive radical hysterectomy for early stage cervical cancer), two new medical technologies guidance (the PLASMA system for transurethral resection and haemostasis of the prostate, and the VAC Veraflo Therapy system for acute infected or chronic wounds), and six Medtech innovation briefings (Optilume for anterior urethral strictures, AI in mammography, AI for analyzing chest CT images, AcQMap for mapping the heart atria to target ablation treatment, and others). Also, two clinical guidelines were updated.Read more
On January 07, 2021, NHS England published an update of the Specialized Services Policy Pipeline (covering the period October 19, 2020 - December 08, 2020). Two new Clinical Commissioning Policies were added to the work program, and six new policies related to radiotherapy, neurosurgery, pulmonology, and in-vitro diagnostics were published.Read more